Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAJ JITENDRA CHOVATIYA

Allopathic & Osteopathic Physicians Dermatology

NPI
1487001822
CMS profile
4218152
Location
CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,000,463.54

737 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $253,376.45 120
ABBVIE INC. $131,483.96 87
PFIZER INC. $104,798.48 43
UCB, Inc. $92,895.14 58
Lilly USA, LLC $55,448.77 59
Arcutis Biotherapeutics, Inc. $52,876.64 40
Regeneron Healthcare Solutions, Inc. $48,745.84 49
Eli Lilly and Company $42,029.19 30
LEO Pharma Inc. $37,873.40 38
SANOFI-AVENTIS U.S. LLC $34,781.29 8
Incyte Corporation $24,975.40 38
Dermavant Sciences, Inc. $23,104.24 27
LEO Pharma AS $21,665.69 36
E.R. Squibb & Sons, L.L.C. $20,173.04 16
Amgen Inc. $17,258.80 36
Galderma Laboratories, L.P. $16,224.98 17
Boehringer Ingelheim Pharmaceuticals, Inc. $15,102.19 10
Takeda Pharmaceuticals U.S.A., Inc. $2,775.00 3
Novartis Pharmaceuticals Corporation $2,760.47 11
Regeneron Pharmaceuticals, Inc. $1,624.00 3
Biofrontera Inc. $215.62 2
Janssen Biotech, Inc. $180.61 5
Verrica Pharmaceuticals Inc. $94.34 1

Page 2 of 15; records 51–100 of 737 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAJ JITENDRA CHOVATIYA

NPI 1487001822 · CMS profile ID 4218152

Allopathic & Osteopathic Physicians / Dermatology

CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 15; records 51–100 of 737 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487001822?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAJ JITENDRA CHOVATIYA, NPI 1487001822, CMS profile ID 4218152. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 15; records 51–100 of 737 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487001822?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RAJ JITENDRA CHOVATIYA, NPI 1487001822, CMS profile ID 4218152. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 15; records 51–100 of 737 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487001822?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RAJ JITENDRA CHOVATIYA, NPI 1487001822, CMS profile ID 4218152, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 15; records 51–100 of 737 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1487001822?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

737 matching records · $1,000,463.54 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 737 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 737.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $925.0012/04/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103132915 CMS
Amgen Inc. $1,722.0012/03/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117526881 CMS
GENZYME CORPORATION $10,248.0012/03/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139908149 CMS
UCB, Inc. $4,850.0012/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143022681 CMS
GENZYME CORPORATION $17.0212/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139907997 CMS
Janssen Biotech, Inc. $19.0512/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078578790 CMS
Lilly USA, LLC $16.2112/02/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155956722 CMS
Incyte Corporation $3,750.0011/26/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141321999 CMS
ABBVIE INC. $950.0011/25/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103132913 CMS
Dermavant Sciences, Inc. $18.9511/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127857487 CMS
LEO Pharma Inc. $72.3411/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152623821 CMS
LEO Pharma Inc. $360.3611/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152623823 CMS
LEO Pharma Inc. $120.5111/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152623825 CMS
Lilly USA, LLC $1,350.0011/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1155953118 CMS
Lilly USA, LLC $3,600.0011/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1155954500 CMS
ABBVIE INC. $126.4511/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103467957 CMS
ABBVIE INC. $1,813.9511/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104180772 CMS
ABBVIE INC. $668.7111/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104180774 CMS
ABBVIE INC. $424.6911/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104180776 CMS
ABBVIE INC. $202.9011/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104180778 CMS
Lilly USA, LLC $706.2011/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135324908 CMS
Lilly USA, LLC $119.6011/20/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155954502 CMS
Takeda Pharmaceuticals U.S.A., Inc. $925.0011/20/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137512268 CMS
ABBVIE INC. $4,625.0011/19/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103145295 CMS
GENZYME CORPORATION $35.8811/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139908075 CMS
GENZYME CORPORATION $53.7111/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139908117 CMS
Dermavant Sciences, Inc. $8,140.0011/16/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127857473 CMS
Dermavant Sciences, Inc. $246.3811/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127857475 CMS
Dermavant Sciences, Inc. $46.8611/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127857477 CMS
Dermavant Sciences, Inc. $34.5611/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127857479 CMS
Dermavant Sciences, Inc. $73.6211/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127857481 CMS
Dermavant Sciences, Inc. $41.7611/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127857483 CMS
Dermavant Sciences, Inc. $14.7711/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127857485 CMS
UCB, Inc. $35.9611/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143022679 CMS
Galderma Laboratories, L.P. $3,120.0011/13/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145290854 CMS
UCB, Inc. $107.4211/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143022675 CMS
UCB, Inc. $526.6211/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143022677 CMS
GENZYME CORPORATION $91.2111/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139907989 CMS
LEO Pharma AS $8,145.0011/11/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152617575 CMS
Lilly USA, LLC $22.8911/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135330317 CMS
PFIZER INC. $4,880.0011/11/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131463793 CMS
ABBVIE INC. $39.1511/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103467955 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,870.0011/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118027295 CMS
PFIZER INC. $1,875.0011/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130873571 CMS
E.R. Squibb & Sons, L.L.C. $4,882.5011/07/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101473813 CMS
LEO Pharma Inc. $2,715.0011/06/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152623815 CMS
LEO Pharma Inc. $783.6711/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152623817 CMS
LEO Pharma Inc. $57.8511/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152623819 CMS
ABBVIE INC. $2,819.1211/04/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103132911 CMS
ABBVIE INC. $711.0011/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104180766 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,345.53 16
PY2020 $1,575.08 7
PY2021 $110,138.89 176
PY2022 $669,735.32 602
PY2023 $690,902.05 594
PY2024 $1,000,463.54 737
PY2025 $1,158,996.92 826

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $22,018.44 16
PY2025 Principal investigator $79,644.50 37
PY2024 Recipient $5,130.00 5
PY2024 Principal investigator $1,104.00 8
PY2023 Recipient $10,098.57 12
PY2022 Recipient $2,540.00 4
PY2021 Recipient $1,600.00 3
PY2020 Recipient $1,200.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

53 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $4,765.50 12/19/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515048
Principal investigator 1 Incyte Corporation $3,256.20 12/04/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515052
Principal investigator 1 Incyte Corporation $1,629.00 11/25/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515043
Principal investigator 1 Incyte Corporation $70.00 10/23/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515003
Principal investigator 1 Incyte Corporation $200.00 10/23/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515007
Principal investigator 1 Incyte Corporation $44.00 10/23/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515019
Principal investigator 1 Incyte Corporation $518.00 10/23/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515024
Principal investigator 1 Incyte Corporation $157.00 10/23/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515029
Principal investigator 1 Incyte Corporation $118.00 10/23/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515033
Principal investigator 1 Incyte Corporation $1,730.70 10/09/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515037
Principal investigator 1 Incyte Corporation $270.00 10/03/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240514996
Principal investigator 1 Incyte Corporation $259.00 10/03/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240514999
Principal investigator 1 Incyte Corporation $7,375.00 10/03/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515011
Principal investigator 1 Incyte Corporation $59.00 10/03/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515015
Principal investigator 1 Incyte Corporation $1,500.00 10/02/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240515056
Principal investigator 1 Incyte Corporation $15,000.00 10/02/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240515060
Recipient Regeneron Pharmaceuticals, Inc. $3,426.80 10/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184116315
Recipient Amgen Inc. $2,027.96 09/22/2025 Covered Recipient Physician A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Ignite) No dispute reported 06/30/2026 1246637012
Principal investigator 1 Incyte Corporation $1,730.70 09/18/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240514992
Recipient PFIZER INC. $940.00 09/17/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726959
Recipient PFIZER INC. $330.00 09/10/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726957
Recipient PFIZER INC. $330.00 09/10/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727341
Principal investigator 1 Incyte Corporation $1,629.00 09/04/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240514988
Recipient PFIZER INC. $940.00 09/04/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726866
Recipient PFIZER INC. $940.00 09/04/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727643
Principal investigator 1 Incyte Corporation $1,629.00 08/26/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240514975
Recipient PFIZER INC. $3,200.00 08/25/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727795
Principal investigator 1 Incyte Corporation $1,629.00 08/14/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240514967
Principal investigator 1 Incyte Corporation $750.00 08/14/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240514971
Principal investigator 1 Incyte Corporation $118.00 08/14/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240514979
Principal investigator 1 Incyte Corporation $923.00 08/14/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240514984
Principal investigator 1 Incyte Corporation $2,114.10 07/31/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240514959
Principal investigator 1 Incyte Corporation $1,629.00 07/22/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240514954
Principal investigator 1 Incyte Corporation $351.00 07/04/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240514963
Principal investigator 1 Incyte Corporation $1,413.00 06/24/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240514925
Principal investigator 1 Incyte Corporation $295.00 06/24/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240514930
Principal investigator 1 Incyte Corporation $431.00 06/24/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240514938
Principal investigator 1 Incyte Corporation $2,465.10 06/24/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240514942
Principal investigator 1 Incyte Corporation $214.20 06/24/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240514951
Principal investigator 1 Incyte Corporation $110.70 06/19/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240514946
Principal investigator 1 Incyte Corporation $8,202.60 06/12/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240514934
Recipient Regeneron Pharmaceuticals, Inc. $640.68 06/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184116313
Principal investigator 1 Incyte Corporation $4,934.70 05/28/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240514922
Recipient PFIZER INC. $330.00 05/08/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228752578
Recipient PFIZER INC. $330.00 05/07/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228759851
Recipient PFIZER INC. $330.00 05/07/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228769921
Recipient Regeneron Pharmaceuticals, Inc. $247.50 05/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184116311
Recipient Regeneron Pharmaceuticals, Inc. $6,431.00 04/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184116309
Recipient PFIZER INC. $940.00 03/07/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228760835
Recipient Regeneron Pharmaceuticals, Inc. $634.50 03/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184116307
Principal investigator 1 Incyte Corporation $9,513.00 02/20/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515065
Principal investigator 1 Incyte Corporation $1,111.00 02/20/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515069
Principal investigator 1 Incyte Corporation $1,500.00 02/20/2025 Non-covered Recipient Entity
CENTER FOR MEDICAL DERMATOLOGY AND IMMUNOLOGY RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515074